肾下极结石手术干预的临床与成本效果:PUrE随机对照试验方案
PUrE试验为多中心随机对照试验,比较输尿管软镜碎石术(FURS)与体外冲击波碎石术(ESWL)或经皮肾镜取石术(PCNL)治疗肾下极结石的临床与成本效果。结石≤10 mm者随机接受FURS或ESWL(RCT1),>10 mm且≤25 mm者随机接受FURS或PCNL(RCT2)。主要临床结局为干预后12周内EQ-5D-5L曲线下面积,主要经济结局为随机化后12个月每质量调整生命年增量成本。
要点
- 肾下极结石约占所有肾结石的35%,且最不易自行排出。
- ≤10 mm结石比较FURS与ESWL,>10 mm且≤25 mm结石比较FURS与PCNL。
- 主要临床结局为12周内EQ-5D-5L曲线下面积,随访至12个月。
核心结论
- 旨在确定FURS相比ESWL或PCNL治疗肾下极结石的临床与成本效果。
研究设计与样本
- 多中心随机对照试验,纳入年龄≥16岁、经CTKUB确诊肾下极结石且需治疗的患者。
- 结石≤10 mm者随机分入FURS或ESWL(RCT1),>10 mm且≤25 mm者随机分入FURS或PCNL(RCT2)。
- 干预后每周问卷随访至12周,随机化后12个月再随访。
关键数值与推荐
- 主要临床结局为干预后12周内基于多次EQ-5D-5L测量的曲线下面积反映的健康状态。
- 主要经济结局为随机化后12个月每获得一个质量调整生命年的增量成本。
- 结石大小分层阈值:≤10 mm进入RCT1,>10 mm且≤25 mm进入RCT2。
临床怎么用
- 为NHS提供三种治疗选项的选择与资源配置证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Renal stones are common, with a lifetime prevalence of 10% in adults. Global incidence is increasing due to increases in obesity and diabetes, with these patient populations being more likely to suffer renal stone disease. Flank pain from stones (renal colic) is the most common cause of emergency admission to UK urology departments. Stones most commonly develop in the lower pole of the kidney (in ~35% of cases) and here are least likely to pass without intervention. Currently there are three technologies available within the UK National Health Service to remove lower pole kidney stones: extracorporeal shockwave lithotripsy (ESWL), percutaneous nephrolithotomy (PCNL) and flexible ureterorenoscopy (FURS) with laser lithotripsy. Current evidence indicates there is uncertainty regarding the management of lower pole stones, and each treatment has advantages and disadvantages. The aim of this trial is to determine the clinical and cost effectiveness of FURS compared with ESWL or PCNL in the treatment of lower pole kidney stones. METHODS: The PUrE (PCNL, FURS and ESWL for lower pole kidney stones) trial is a multi-centre, randomised controlled trial (RCT) evaluating FURS versus ESWL or PCNL for lower pole kidney stones. Patients aged ≥16 years with a stone(s) in the lower pole of either kidney confirmed by non-contrast computed tomography of the kidney, ureter and bladder (CTKUB) and requiring treatment for a stone ≤10 mm will be randomised to receive FURS or ESWL (RCT1), and those requiring treatment for a stone >10 mm to ≤25 mm will be randomised to receive FURS or PCNL (RCT2). Participants will undergo follow-up by questionnaires every week up to 12 weeks post-intervention and at 12 months post-randomisation. The primary clinical outcome is health status measured by the area under the curve calculated from multiple measurements of the EuroQol five dimensions five-level version (EQ-5D-5L) questionnaire up to 12 weeks post-intervention. The primary economic outcome is the incremental cost per quality-adjusted life year gained at 12 months post-randomisation. DISCUSSION: The PUrE trial aims to provide robust evidence on health status, quality of life, clinical outcomes and resource use to directly inform choice and National Health Service provision of the three treatment options. TRIAL REGISTRATION: ISRCTN: ISRCTN98970319. Registered on 11 November 2015.
引用
- McClinton S, Starr K, Thomas R, et al. The clinical and cost effectiveness of surgical interventions for stones in the lower pole of the kidney: the percutaneous nephrolithotomy, flexible ureterorenoscopy and extracorporeal shockwave lithotripsy for lower pole kidney stones randomised controlled trial (PUrE RCT) protocol. Trials. 2020. PMID: 32498699. doi:10.1186/s13063-020-04326-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。